Jul 21, 2026
Forge Biologics has partnered with Restore Vision to manufacture RV-001, a gene therapy for retinitis pigmentosa in Phase 1/2 trials in Japan. Forge also announced seven presentations at the ASGCT 29th Annual Meeting, highlighting process innovation and late-phase manufacturing capabilities. The company's CTO further discussed industrial-scale AAV gene therapy on The Genetics Podcast.
Jun 14, 2026
Three biotech companies announce significant funding: Korsana Biosciences secures $175 million for neurodegenerative therapies, Kos Biotechnology Partners closes a $123 million life sciences fund, and ParcelBio launches with $13 million to advance mRNA medicines.
May 16, 2026
Benitec Biopharma's gene therapy BB-301 improved swallowing ability in all four OPMD patients followed for at least one year in a Phase Ib/II trial. One patient showed continued improvement at two years. The company plans to meet with the FDA in mid-2026 to discuss a pivotal study.
Apr 06, 2026
The microfluidics market is projected to grow from $10.33 billion in 2025 to $20.73 billion by 2030. Growth is tied to lab-on-a-chip research, miniaturized diagnostics, and pharmaceutical R&D adoption.
